The short version of GW501516 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-30 and is reviewed periodically as new material appears.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
=== U.S. license to sell Venezuelan oil to Cuba === On 25 February, the United States emitted a license allowing companies to resell Venezuelan oil to Cuba's private sector. The U.S. Treasury Department indicated that the exchange must "support the Cuban people, including the private sector".
=== Origins === Chronic widespread pain had been described in the literature in the 19th century. Fibromyalgia was first recognized in the 1950s. Many names, including muscular rheumatism, fibrositis, psychogenic rheumatism, and neurasthenia had been applied historically to symptoms resembling those of fibromyalgia. The term fibromyalgia was first used in 1976, when Phillip Kahler Hench used it to describe widespread pain symptoms, and it was used by researcher Mohammed Yunus in a scientific publication in 1981. A 1977 paper on fibrositis by Smythe and Moldofsky was important in the development of the fibromyalgia concept. The first clinical, controlled study of the characteristics of fibromyalgia syndrome was published in 1981, providing support for symptom associations. In 1984, an interconnection between fibromyalgia syndrome and other similar conditions was proposed, and in 1986, trials of the first proposed medications for fibromyalgia were published. A 1987 article in the Journal of the American Medical Association used the term 'fibromyalgia syndrome', while saying it was a "controversial condition". The American College of Rheumatology (ACR) published its first classification criteria for fibromyalgia in 1990. Later revisions were made in 2010, 2016, and 2019.
However, the dependence on some of these properties is negligible in certain cases. For example, the viscosity of a Newtonian fluid does not vary significantly with the rate of deformation. Zero viscosity (no resistance to shear stress) is observed only at very low temperatures in superfluids; otherwise, the second law of thermodynamics requires all fluids to have positive viscosity. A fluid that has zero viscosity (non-viscous) is called ideal or inviscid. For non-Newtonian fluids' viscosity, there are pseudoplastic, plastic, and dilatant flows that are time-independent, and there are thixotropic and rheopectic flows that are time-dependent.
Sources: en.wikipedia.org
== External links == Protamine+Sulfate at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "Protamine Sulfate". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on August 29, 2021.
=== Multiple Reaction Monitoring (MRM) === Although MRM has been used extensively in metabolomics and proteomics, its high sensitivity and linear response over a wide dynamic range make it especially suited for glycan biomarker research and discovery. MRM is performed on a triple quadrupole (QqQ) instrument, which is set to detect a predetermined precursor ion in the first quadrupole, a fragmented in the collision quadrupole, and a predetermined fragment ion in the third quadrupole. It is a non-scanning technique, wherein each transition is detected individually and the detection of multiple transitions occurs concurrently in duty cycles. This technique is being used to characterize the immune glycome. Table 1:Advantages and disadvantages of mass spectrometry in glycan analysis
In the presence of acid, hemiacetals can undergo an elimination reaction, losing the oxygen atom that once belonged to the parent aldehyde’s carbonyl group. These oxonium ions are powerful electrophiles, and react rapidly with a second molecule of alcohol to form new, stable compounds, called acetals. The whole mechanism of acetal formation from hemiacetal is drawn below.
{\displaystyle {\begin{aligned}\varphi :\ &\rho \left({\partial _{t}u_{\varphi }}+u_{r}{\partial _{r}u_{\varphi }}+{\frac {u_{\varphi }}{r}}{\partial _{\varphi }u_{\varphi }}+u_{z}{\partial _{z}u_{\varphi }}+{\frac {u_{r}u_{\varphi }}{r}}\right)\\&\quad =-{\frac {1}{r}}{\partial _{\varphi }p}\\&\qquad +\mu \left({\frac {1}{r}}\ \partial _{r}\left(r{\partial _{r}u_{\varphi }}\right)+{\frac {1}{r^{2}}}{\partial _{\varphi }^{2}u_{\varphi }}+{\partial _{z}^{2}u_{\varphi }}-{\frac {u_{\varphi }}{r^{2}}}+{\frac {2}{r^{2}}}{\partial _{\varphi }u_{r}}\right)\\&\qquad +{\frac {1}{3}}\mu {\frac {1}{r}}\partial _{\varphi }\left({\frac {1}{r}}{\partial _{r}\left(ru_{r}\right)}+{\frac {1}{r}}{\partial _{\varphi }u_{\varphi }}+{\partial _{z}u_{z}}\right)\\&\qquad +\rho g_{\varphi }\\[8px]\end{aligned}}}
Sources: en.wikipedia.org
The previous term PCOS was considered "inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy framing." The new term reflects "the condition's multisystem pathophysiology", and is more accurate by omitting cysts.
==== Ductal development ==== Though to a far lesser extent than estrogen, which is the major mediator of mammary ductal development (via the ERα), progesterone may also be involved in ductal development of the mammary glands to some extent. PR knockout mice or mice treated with the PR antagonist mifepristone show delayed although otherwise normal mammary ductal development at puberty. In addition, mice modified to have overexpression of PRA display ductal hyperplasia, and progesterone induces ductal growth in the mouse mammary gland. Progesterone mediates ductal development mainly via induction of the expression of amphiregulin, the same growth factor that estrogen primarily induces the expression of to mediate ductal development. These animal findings suggest that, while not essential for full mammary ductal development, progesterone seems to play a potentiating or accelerating role in estrogen-mediated mammary ductal development.
=== CPM, thiol-specific dyes === Alexandrov et al. (2008) published a variation on the Thermofluor assay where SYPRO Orange was replaced by N-[4-(7-diethylamino-4-methyl-3-coumarinyl)phenyl]maleimide (CPM), a compound that only fluoresces after reacting with a nucleophile. CPM has a high preference for thiols over other typical biological nucleophiles and therefore will react with cysteine side chains before others. Cysteines are typically buried in the interior of a folded protein as they are hydrophobic. When a protein denatures cysteine thiols become available and a fluorescent signal can be read from reacted CPM. The excitation and emission wavelengths for reacted CPM are 387 nm/ 463 nm so a fluorescence plate reader or a qPCR machine with specialized filters is required. Alexandrov et al. used the technique successfully on the membrane proteins Apelin GPCR and FAAH as well as β-lactoglobin which fibrillates on heating rather than going to a molten globule.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.